Insurers, here's how behavioural science can help you navigate the GLP-1 medication era

The buzz around GLP-1 receptor agonists stems from the evidenced success for weight loss 1 2and improvement in obesity-related comorbidities 3. While much has been written on the biological mechanisms of GLP-1 medications, we focus on the importance of considering behavioural science approaches during this time. Long-term impact hinges not solely on medication but also on patient behaviour. Insurers can leverage behavioural science to improve the health outcomes of policyholders and better assess applicants' risk in this GLP-1 drug era.

Key Takeaways of the publication:

  1. A key challenge for adopters of GLP-1 medications, such as Ozempic® and Wegovy®, is the potential of weight regain after discontinuing the drug 4 As such, the long-term impact of GLP-1 drugs hinges not solely on the medication intake but also on patient behaviour and sustained lifestyle change.
  2. Pricing risks accurately in the era of GLP-1 medications is a key challenge for insurers. Underwriting questions informed by behavioural science can build trust and encourage accurate and honest disclosures, allowing insurers to collect valuable information and avoid mispricing of risk.
  3. Insurance health and wellbeing offerings can leverage learnings from behavioural science research to optimise sustained behavioural change among policyholders.

How can Swiss Re help you?

Swiss Re is dedicated to improving the customer experience and delivering meaningful value to policyholders by partnering with our clients. The examples included in this publication demonstrate some techniques that Swiss Re's Customer Experience and Engagement teams have applied across the customer journey for improved customer outcomes. Additionally, for insurers looking to proactively offer customers targeted wellbeing support, Swiss Re has partnered with specialist providers who deliver proven and personalised health programmes for select cohorts – whether new or existing policyholders at the point of claim – to help them improve and sustain holistic health outcomes. Please reach out if you're interested in learning more.

References

References

1 Once-Weekly Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine.

2 Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis, BMJ.

3 Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, The Lancet Diabetes & Endocrinology

4 A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity, Journal of Obesity

Tags

The GLP-1 Medication Era: Insurers, here's how behavioural science can help you navigate the GLP-1 era

Contact Authors

Read more Related content

Reinsurance Insights

We’re here to help our clients succeed, and apply our knowledge to their specific needs. We are experts on current and emerging topics. Through our global reach, we are able to aggregate information across markets to benefit our clients. Here is a selection of our most recent insights on topics relevant to our reinsurance clients, distribution partners and society as a whole.